Related references
Note: Only part of the references are listed.Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor
Joseph E. Grossman et al.
ONCOGENE (2021)
Immunotherapy: The end of the dark age for metastatic triple-negative breast cancer?
Michela Palleschi et al.
BREAST JOURNAL (2020)
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
S. Adams et al.
ANNALS OF ONCOLOGY (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
Hua Guo et al.
BREAST CANCER RESEARCH (2020)
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Jeffrey M. Conroy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here
Maryann J. Kwa et al.
CANCER (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K. Beckers et al.
HISTOPATHOLOGY (2016)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Classical pathology and mutational load of breast cancer - integration of two worlds
Jan Budczies et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2015)
The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity
Suzanne Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2014)
Making Genuine Progress Against Metastatic Breast Cancer
Gary H. Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Share Paper
